重组人血管内皮抑素治疗初治广泛期小细胞肺癌的效果(1)
【摘要】 目的：评价初治的广泛期小细胞肺癌(SCLC)患者接受依托泊苷和顺铂化疗(EP方案)联合重组人血管内皮抑制素注射液治疗对比单独EP方案化疗是否具有更好的临床效果。方法：选取本院2017年3月-2019年9月收治的60例广泛期小细胞肺癌初治患者作为研究对象，采取随机分配方式，按1∶1分为试验组(重组人血管内皮抑素联合EP方案)和对照组(EP方案)，对比两组的有效性与安全性。结果：试验组的疾病控制率为96.7%，高于对照组的73.3%(P<0.05)。试验组PFS略长于对照组，两组比较差异无统计学意义(P>0.05)，试验组Ⅲ级不良反应发生率为0，低于对照组的26.7%(P<0.05)。结论：广泛期小细胞肺癌初治患者的临床治疗中，应用依托泊苷和顺铂进行化疗的基础上，联合应用重组人血管内皮抑素，能够有效提高疾病控制率，降低化疗毒副反应的发生，以提高患者生活质量。
【关键词】 重组人血管内皮抑素 依托泊苷 顺铂 广泛期小细胞肺癌
doi：10.14033/j.cnki.cfmr.2020.26.004 文献标识码 A 文章编号 1674-6805(2020)26-00-03
Efficacy of Recombinant Human Endostatin in the Treatment of Newly Diagnosed Extensive Small Cell Lung Cancer/ZHOU Zhan， CHEN Qiaolin， ZHENG Xiuxia， FANG Minshan， SHI Qin. //Chinese and Foreign Medical Research， 2020， 18(26)： -13
[Abstract] Objective： To evaluate the efficacy of Etoposide and Cisplatin chemotherapy combined with Recombinant Human Vascular Endostatin Injection in the treatment of patients with extensive small cell lung cancer (SCLC) compared with EP project alone. Method： A total of 60 patients with extensive small cell lung cancer who treated in our hospital from March 2017 to September 2019 were randomly divided into the experimental group (Recombinant Human Endostatin Injection combined with EP project) and the control group (EP project)， with 30 cases in each group. The effectiveness and safety in two groups were compared. Result： DCR of the experimental group was 96.7%， which was higher than 73.3% of the control group (P<0.05). PFS of the experimental group was longer than that of the control group， but there was no statistically significant difference in PFS between the two groups (P>0.05). The incidence rate of Ⅲ grade adverse reactions in the experimental group was 0， which was lower than 26.7% of the control group (P<0.05). Conclusion： The combination of Etoposide and Cisplatin with Recombinant Human Vascular Endostatin can improve the rate of disease control， reduce the occurrence of side effects of chemotherapy and improve the life quality of patients with extensive small cell lung cancer.
[Key words] Recombinant Human Vascular Endostatin Etoposide Cisplatin Extensive small cell lung cancer
First-author’s address： Fuzhou Pulmonary Hospital， Fuzhou 350007， China
小細胞肺癌(small cell lung cancer，SCLC)占所有肺癌的15%～20%。SCLC可分为局限期(limited disease)和广泛期(extensive disease)两期。局限期的特点是肿瘤局限于一侧胸腔内，包括有锁骨上或前斜角肌淋巴结转移和同侧胸腔积液。广泛期的特点是病变超过局限型范围[1]。2/3以上SCLC患者确诊时已为广泛期，若不治疗中位生存期仅为6～12周，联合化疗后可达7～9个月[2]。在过去的20年中，广泛期SCLC的治疗罕有突破性进展。目前广泛期SCLC的标准化疗方案为依托泊苷+顺铂(EP方案)或卡柏+依托泊苷(CE方案)，其有效率达到了治疗的瓶颈。抗血管生成治疗的靶目标是肿瘤血管内皮细胞，通过抑制新血管生成，间接抑制肿瘤细胞生长和转移，因此其用药方式也应符合内皮细胞的生理特性。抗新生血管治疗是一个长期、慢性的治疗过程，由于血管内皮抑素具有广谱、低毒特性，对神经内分泌肿瘤有效，与化疗联合具协同作用，而广泛期SCLC的疗效还有待进一步提高，因此有必要对血管内皮抑素联合化疗治疗SCLC做深入研究。, http://www.100md.com(周展 陈巧林 郑秀霞 方闽汕 石琴)
【关键词】 重组人血管内皮抑素 依托泊苷 顺铂 广泛期小细胞肺癌
doi：10.14033/j.cnki.cfmr.2020.26.004 文献标识码 A 文章编号 1674-6805(2020)26-00-03
Efficacy of Recombinant Human Endostatin in the Treatment of Newly Diagnosed Extensive Small Cell Lung Cancer/ZHOU Zhan， CHEN Qiaolin， ZHENG Xiuxia， FANG Minshan， SHI Qin. //Chinese and Foreign Medical Research， 2020， 18(26)： -13
[Abstract] Objective： To evaluate the efficacy of Etoposide and Cisplatin chemotherapy combined with Recombinant Human Vascular Endostatin Injection in the treatment of patients with extensive small cell lung cancer (SCLC) compared with EP project alone. Method： A total of 60 patients with extensive small cell lung cancer who treated in our hospital from March 2017 to September 2019 were randomly divided into the experimental group (Recombinant Human Endostatin Injection combined with EP project) and the control group (EP project)， with 30 cases in each group. The effectiveness and safety in two groups were compared. Result： DCR of the experimental group was 96.7%， which was higher than 73.3% of the control group (P<0.05). PFS of the experimental group was longer than that of the control group， but there was no statistically significant difference in PFS between the two groups (P>0.05). The incidence rate of Ⅲ grade adverse reactions in the experimental group was 0， which was lower than 26.7% of the control group (P<0.05). Conclusion： The combination of Etoposide and Cisplatin with Recombinant Human Vascular Endostatin can improve the rate of disease control， reduce the occurrence of side effects of chemotherapy and improve the life quality of patients with extensive small cell lung cancer.
[Key words] Recombinant Human Vascular Endostatin Etoposide Cisplatin Extensive small cell lung cancer
First-author’s address： Fuzhou Pulmonary Hospital， Fuzhou 350007， China
小細胞肺癌(small cell lung cancer，SCLC)占所有肺癌的15%～20%。SCLC可分为局限期(limited disease)和广泛期(extensive disease)两期。局限期的特点是肿瘤局限于一侧胸腔内，包括有锁骨上或前斜角肌淋巴结转移和同侧胸腔积液。广泛期的特点是病变超过局限型范围[1]。2/3以上SCLC患者确诊时已为广泛期，若不治疗中位生存期仅为6～12周，联合化疗后可达7～9个月[2]。在过去的20年中，广泛期SCLC的治疗罕有突破性进展。目前广泛期SCLC的标准化疗方案为依托泊苷+顺铂(EP方案)或卡柏+依托泊苷(CE方案)，其有效率达到了治疗的瓶颈。抗血管生成治疗的靶目标是肿瘤血管内皮细胞，通过抑制新血管生成，间接抑制肿瘤细胞生长和转移，因此其用药方式也应符合内皮细胞的生理特性。抗新生血管治疗是一个长期、慢性的治疗过程，由于血管内皮抑素具有广谱、低毒特性，对神经内分泌肿瘤有效，与化疗联合具协同作用，而广泛期SCLC的疗效还有待进一步提高，因此有必要对血管内皮抑素联合化疗治疗SCLC做深入研究。, http://www.100md.com(周展 陈巧林 郑秀霞 方闽汕 石琴)